17 May 2018 - - Barcelona, Spain-based global healthcare company Grifols (MCE: GRF, GRF.P, and NASDAQ: GRFS) has expanded its blood typing solutions portfolio in the US with the addition of antisera reagents, the company said.
The US Food and Drug Administration recently granted licensing approval for Grifols to commercialize a range of antisera reagents designed for routine and complex immunohematology testing.
Manual techniques for blood typing and pretransfusion testing continue to be a large segment in the US blood transfusion industry.
To meet the growing demand for innovative blood typing solutions, Grifols comprehensive portfolio now includes ABO and Rh monoclonal antisera, rare antigen antisera, and anti-human globulin sera. Most of these reagents require no incubation time.
Grifols is producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and immune globulin products for patients. Its three main divisions--bioscience, diagnostic, and hospital--develop, produce, and market innovative products and services that are available in more than 100 countries.
The company has approximately 18,000 employees in 30 countries.